APA (7th ed.) Citation

SG, H., EE, M., D, M., AB, V., CM, H., E, A., . . . LJ, P. (2019). A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge. Science translational medicine, 11(501), . https://doi.org/10.1126/scitranslmed.aaw2607

Chicago Style (17th ed.) Citation

SG, Hansen, et al. "A Live-attenuated RhCMV/SIV Vaccine Shows Long-term Efficacy Against Heterologous SIV Challenge." Science Translational Medicine 11, no. 501 (2019). https://doi.org/10.1126/scitranslmed.aaw2607.

MLA (9th ed.) Citation

SG, Hansen, et al. "A Live-attenuated RhCMV/SIV Vaccine Shows Long-term Efficacy Against Heterologous SIV Challenge." Science Translational Medicine, vol. 11, no. 501, 2019, https://doi.org/10.1126/scitranslmed.aaw2607.